Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab in advanced cervical cancer
NCT06714084Enrolling by invitation
- Sponsor
- Hubei Cancer Hospital
- Start
- Oct 2024
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of cadonilimab in Cervical Cancer (CC), sponsored by Hubei Cancer Hospital. Primary endpoints: Progression-Free Survival Rate at 12 months and Objective Response Rate at 2 months. Started Oct 2024; status: enrolling by invitation.
02
Drugs
cadonilimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06714084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06714084.